<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04581057</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2019/18</org_study_id>
    <nct_id>NCT04581057</nct_id>
  </id_info>
  <brief_title>Correlation Between Clonal Hematopoiesis, Cardio-vascular Events, Inflammation and Atherosclerosis</brief_title>
  <acronym>CHATH</acronym>
  <official_title>Frequency of Clonal Hematopoiesis in Patients Over 75 With a First Cardio Vascular Event. Consequences on Inflammation and Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at evaluating the prevalence of Clonal Hematopoiesis of Indeterminate&#xD;
      Potential (CHIP) in patients over 75 presenting with a first cardio-vascular event (CVE). The&#xD;
      investigators will also determine if CHIPs are more frequent in this population compared to a&#xD;
      control cohort without CVE. An association between CHIP, a systemic inflammation and&#xD;
      increased atherosclerosis will also be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite increasing knowledge on the pathophysiology of cardio-vascular diseases (in&#xD;
      particular the role of inflammation in the development of atherosclerosis), predicting their&#xD;
      occurrence remains largely difficult. Aging remains the most powerful factor for predicting&#xD;
      the occurrence of myocardial infarction, independently from other identified risk factors.&#xD;
      Few years ago, acquired mutations were described in the hematopoietic system of apparently&#xD;
      healthy subjects. This phenomenon, now described as CHIP (Clonal Hematopoiesis of&#xD;
      Indeterminate Potential) is more frequently observed in elderly people, and has been recently&#xD;
      linked to an increased risk of cardio-vascular events. Experiments in mice demonstrated that&#xD;
      these CHIPs are responsible for an inflammation that supports the development of&#xD;
      atherosclerosis. However the link between CHIP, inflammation and atherosclerosis has never&#xD;
      been demonstrated in humans.&#xD;
&#xD;
      In this study, the investigators will search for an increased frequency of CHIP in patients&#xD;
      with a first cardio-vascular event (CVE). Seven months after the CVE, a blood sample will be&#xD;
      taken. Mutations in the 9 most frequently mutated genes in CHIP will be evaluated by Next&#xD;
      Generation Sequencing. Systemic inflammation will be evaluated by measurement of circulating&#xD;
      levels of CRP, IL-1β, IL-6, IL-10 and TNF-α. Atherosclerosis will be evaluated via the volume&#xD;
      of atherosclerotic plaques as assessed by 3D ultrasound analysis. The presence of CHIP will&#xD;
      be correlated to traditional cardiovascular risk factors, systemic inflammation markers and&#xD;
      the level of atherosclerosis. The investigators will also assess the relationship between the&#xD;
      presence of CHIP and the risk of CVE reoccurrence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2020</start_date>
  <completion_date type="Anticipated">June 23, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 23, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of a CHIP</measure>
    <time_frame>Day 1</time_frame>
    <description>Defined as the presence of a mutation (in the genes DNMT3A, TET2, ASXL1, SF3B1, TP53, CBL, SRSF2, GNB1 and PPM1D) (with an allelic frequency greater than 2, 5 or 10%).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of CHIP</measure>
    <time_frame>Day 1</time_frame>
    <description>The frequency of CHIP in this cohort will be compared to the one observed in a control population (recruited from the 3-cities study cohort or 3C).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of systemic inflammation</measure>
    <time_frame>Day 1</time_frame>
    <description>Assessed by the level of plasmatic CRP, IL-1β, IL-6, IL-10 and TNF-α.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Atherosclerosis level</measure>
    <time_frame>Day 1</time_frame>
    <description>Assessed by 3D ultrasound analysis. An innovative technique for monitoring the volume of carotid plaques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of cardiovascular risk factor</measure>
    <time_frame>Day 1</time_frame>
    <description>Evaluated by the investigators.The cardiovascular risk factor are defined as :&#xD;
Active smoking or smoking cessation for less than 3 years&#xD;
HyperLDLemia (LDL Cholesterol &gt; 3.36 mmol/L)&#xD;
HypoHDLemia (HDL &lt; 1.03 mmol/L in men or &lt; 1.29 mmol/L in women)&#xD;
Diabetes (2 blood glucose levels &gt; 6.93 mmol/L)&#xD;
Hypertension (hypertension) (&gt; 140/90 mmHg) treated or not.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>First CVE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Specific blood sampling</intervention_name>
    <description>A 30 ml blood sample (6 EDTA tubes) will be taken at inclusion in the study, in addition to the blood sample taken as part of the routine care.&#xD;
This sampling is carried out for :&#xD;
Search for CHIP-associated mutations in circulating leukocytes&#xD;
Plasma determination of IL-1β, IL-6, IL-10 and TNF-α</description>
    <arm_group_label>First CVE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients (male or female) over 75 years old&#xD;
&#xD;
          -  Patients with a first CVE (myocardial infarction) of atheromatous origin that occurred&#xD;
             between 2 and 7 months before inclusion&#xD;
&#xD;
          -  Absence of evidence of hematological malignancy (known or obvious by the results of&#xD;
             blood counts)&#xD;
&#xD;
          -  Subject registered with a social security scheme&#xD;
&#xD;
          -  Written informed consent obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who did not presented any CVE in the last 7 months&#xD;
&#xD;
          -  Patients with CVE with a non-atheromatous origin (dissection, embolic, …)&#xD;
&#xD;
          -  Presence of an unbalanced diabetes (defined as HbA1C &gt; 10%)&#xD;
&#xD;
          -  History of previous CVE before 75 year-old : myocardial infarction, stroke of&#xD;
             atheromatous origin&#xD;
&#xD;
          -  Hematological malignancy (known or obvious on the results of blood counts)&#xD;
&#xD;
          -  Chronic inflammatory disease (cancer, vasculitis, rheumatism, hepato-gastro-intestinal&#xD;
             diseases).&#xD;
&#xD;
          -  Long term anti-inflammatory treatments:&#xD;
&#xD;
               -  Corticoids&#xD;
&#xD;
               -  Nonsteroidal anti-inflammatory drugs&#xD;
&#xD;
               -  Aspirin (&gt; 325 mg per day)&#xD;
&#xD;
               -  Cyclo-oxygenase II inhibitors&#xD;
&#xD;
          -  Persons under judicial safeguards, trustee or curators&#xD;
&#xD;
          -  Person deprived of judicial or administrative freedom&#xD;
&#xD;
          -  Person unable to give her consent&#xD;
&#xD;
          -  Non-cooperative person&#xD;
&#xD;
          -  Exclusion period after another clinical study or participation to another&#xD;
             interventional clinical study testing a drug in the 30 days before inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry COUFFINHAL, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thierry COUFFINHAL, MD-PhD</last_name>
    <phone>(0)5 57 65 69 70</phone>
    <phone_ext>+33</phone_ext>
    <email>thierry.couffinhal@inserm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthieu MEILLAN</last_name>
    <phone>(0)5 57 65 69 96</phone>
    <phone_ext>+33</phone_ext>
    <email>matthieu.meillan@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry COUFFINHAL, MD-PhD</last_name>
      <phone>(0)5 57 65 69 70</phone>
      <phone_ext>+33</phone_ext>
      <email>thierry.couffinhal@inserm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Matthieu MEILLAN</last_name>
      <phone>(0)5 57 65 69 96</phone>
      <phone_ext>+33</phone_ext>
      <email>matthieu.meillan@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Thierry COUFFINHAL, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yann PUCHEU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chloé JAMES, MD-PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier MANSIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Audrey BIDET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CHIP</keyword>
  <keyword>Cardiovascular events</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

